GlassScriptPhysician profile
Angela S Declue
NPI 1659343903
$5,765.47
in general payments reported to CMS, 2019-2025
37 companies · $303 in 2025
The $303 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,763 · 2022: $1,589 · 2023: $1,223 · 2024: $888 · 2025: $303.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,413.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,413.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,176.90 | 2021-2025 | |
| Lilly USA, LLC | $453.89 | 2021-2025 | Mounjaro, Trulicity, Zepbound |
| Amarin Pharma, INC. | $219.89 | 2021-2022 | |
| Glaxosmithkline, LLC. | $201.50 | 2021-2024 | Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $176.15 | 2021-2023 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $157.95 | 2021-2023 | Saphnelo |
| Biohaven Pharmaceutical Holding Company LTD. | $121.02 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $117.16 | 2021 | |
| Amgen INC. | $106.26 | 2021-2023 | Otezla, Repatha |
| Novo Nordisk INC | $90.22 | 2021-2023 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.94 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $83.29 | 2024-2025 | Rexulti |
| Exact Sciences Corporation | $71.91 | 2024-2025 | Cologuard Collection Kit |
| Pfizer INC. | $68.36 | 2023-2025 | |
| Sunovion Pharmaceuticals INC. | $59.58 | 2021 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $57.76 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $48.36 | 2021-2023 | |
| Sumitomo Pharma America, INC. | $43.74 | 2023 | Aptiom, Gemtesa |
| Xeris Pharmaceuticals, INC. | $41.62 | 2023 | Gvoke Hypopen |
| Lundbeck LLC | $35.97 | 2023-2024 | Rexulti |
| Axsome Therapeutics, INC. | $32.95 | 2022 | |
| Boston Scientific Corporation | $31.40 | 2022-2024 | Spyglass Discover |
| Merck Sharp & Dohme LLC | $28.09 | 2021 | |
| Esperion Therapeutics, INC. | $27.74 | 2021 | |
| Phathom Pharmaceuticals, INC. | $27.00 | 2024 | Voquezna |
| Tactile Systems Technology INC | $23.45 | 2022 | |
| Janssen Pharmaceuticals, INC | $22.29 | 2024 | Spravato |
| Gilead Sciences, INC. | $21.04 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.98 | 2022 | |
| Ironwood Pharmaceuticals, INC | $17.10 | 2021 | |
| Nevro Corp. | $16.71 | 2024 | Senza |
| Abbott Laboratories | $15.51 | 2025 | Freestyle Libre |
| Supernus Pharmaceuticals, INC. | $15.21 | 2021 | |
| Masimo Corporation | $14.49 | 2022 | |
| Astellas Pharma US INC | $13.96 | 2023 | Veozah |
| Sanofi-Aventis U.S. LLC | $12.90 | 2022 | |
| Grifols USA, LLC | $11.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Declue listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.